查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2017230

羊膜市場：按形態、原料、應用和最終用戶分類－2026-2032年全球市場預測

Amniotic Membrane Market by Form, Source, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，羊膜市值將達到 39.4 億美元，到 2026 年將成長至 42.9 億美元，到 2032 年將達到 73.4 億美元，複合年成長率為 9.28%。

主要市場統計數據
基準年 2025 39.4億美元
預計年份：2026年 42.9億美元
預測年份 2032 73.4億美元
複合年成長率 (%) 9.28%

全面介紹羊膜科學及其臨床效用，概述目前推動整個治療領域採用和創新途徑的因素。

羊膜因其獨特的生物學特性，能夠促進傷口癒合和組織再生，作為一種效用廣泛的生物材料，正受到越來越多的關注。其細胞外基質組成、固有的抗發炎和抗纖維化因子以及相對的免疫豁免特性，使其成為眼科、創傷護理、牙科和整形外科手術中極具吸引力的輔助性治療。隨著外科、再生醫學和組織工程領域的相關人員尋求能夠簡化治療流程並改善患者預後的解決方案，羊膜的應用正從局部小局部轉向綜合治療。

醫療服務領域的技術、監管和變革正在重塑整個醫療體系中羊膜產品的設計、臨床應用和採購要求。

羊膜領域正經歷著由技術、監管和臨床因素共同驅動的變革，這些因素正在重塑製造商和醫療保健提供者的價值提案。保存和加工技術的創新，例如最佳化的冷凍保存方案、先進的脫水技術和可控凍乾，在保持關鍵生物活性的同時，提高了儲存穩定性和物流效率。這些技術進步正吸引非眼科專業的關注，並促進了產品在創傷護理基質和整形外科支架等領域的應用。

評估 2025 年關稅變化對羊膜供應鏈、採購選擇和區域製造應對措施在臨床護理方面的廣泛下游影響。

2025年實施的貿易政策變化和關稅調整，迫使組織衍生醫療產品的國際供應鏈和籌資策略進行重新評估。關稅的徵收可能會增加進口原料和成品羊膜產品的成本，迫使製造商和買家重新評估其採購系統和與供應商的關係。為此，一些製造商正在加快關鍵製作流程的在地化進程，並實現採購來源多元化，以降低單一國家關稅的影響。

將產品形式、生物來源、臨床用途和最終用戶環境聯繫起來的詳細細分分析，可提供有針對性的開發和商業化途徑。

細分市場分析揭示了產品形態、生物來源、臨床應用和終端用戶環境等方面的不同趨勢，這些趨勢共同影響研發重點和產品上市路徑。依形態分類，市場分為冷凍保存、脫水、新鮮和凍乾四類，每種形態都有其獨特的優點和物流考量。冷凍保存形態保持了較高的生物活性，但需要低溫運輸物流。脫水和凍乾形態提高了保存期限和操作便利性，但需要檢驗的複水方案。新鮮形態雖然使用時間有限，但能最大程度即時保留其天然特性。依來源分類，市場分為牛、馬源和人源三類，每種來源的免疫抗原性原性、供體篩檢要求和臨床醫生接受度各不相同，這些因素都會影響監管和倫理方面的考慮。

區域趨勢導致美洲、歐洲、中東和非洲以及亞太地區的市場在臨床接受度和供應韌性方面存在差異，以及針對這些趨勢的策略性製造應對措施。

區域趨勢對臨床應用、監管預期和生產策略有顯著影響，美洲、歐洲、中東和非洲以及亞太地區的趨勢截然不同。在美洲，由於成熟的組織庫和整合的分銷管道，門診和專科診所正在迅速採用組織移植，但報銷機制各不相同，需要以循證醫學為基礎進行市場定位。在歐洲、中東和非洲，監管協調的努力以及對捐贈者篩檢和可追溯性的重視正在影響製造商對品質系統的投資。同時，一些地區選擇性的報銷政策正在推動醫療主導計畫中的組織移植快速普及。

以擴大生產規模、垂直整合、建立基於證據的夥伴關係以及提供差異化服務為重點的競爭性和策略性企業行動正在推動市場領導地位。

羊膜領域的主要企業正採取互補策略，將技術改進、強化品質系統和合作臨床檢驗結合。許多企業正投資擴大生產規模並檢驗的儲存流程，以確保不同產品形式的效能一致性。另一些企業則優先考慮垂直整合，以確保供體組織來源並增強可追溯性，從而應對日益嚴格的監管審查，並讓大規模醫療機構買家放心。與學術機構、專科診所和創傷護理網路建立策略合作夥伴關係，有助於證據的產生，並為早期採用者加速臨床應用鋪平道路。

為製造商和相關人員提供可操作的策略重點，以增強羊膜部署中的採購韌性、證據產生和服務主導差異化。

產業領導者應推動一系列合作舉措，以確保臨床應用、營運韌性和持續創新。首先，應實現籌資策略多元化，並投資於區域加工能力，以降低貿易和物流風險，同時維持產品品質和可追溯性。其次，應優先最佳化儲存和包裝，使產品特性適應特定的臨床工作流程，並降低門診和住院環境中的操作複雜性。第三，應加強與監管機構和支付相關人員的溝通，並基於臨床結果和下游流程資源利用率的降低，清楚闡述價值提案，從而加強醫保報銷方面的對話。

為了支持對羊膜發育進行可重複和實用的見解，採用了一種透明的、基於三角測量的調查方法，結合了專家訪談、監管分析和情境評估。

本研究採用三角測量法整合一手和二手證據，旨在確保研究結果的準確性、相關性和可重複性。一手資料包括對眼科、創傷護理、牙科和整形外科臨床意見領袖的結構化訪談，並輔以與負責人和監管專家的討論，以了解營運限制和政策影響。二手資料包括同行評審文獻、監管指導文件、會議論文集和檢驗的技術白皮書，這些資料闡明了保守的科學觀點和臨床結果。來自多個資訊來源的數據經過交叉核對，並透過反覆的專家檢驗來調和相互衝突的觀點，以最大限度地減少偏見，並儘可能得出反映共識的結論。

最終將臨床可行性、營運限制和策略挑戰整合起來，這將決定哪些組織能夠將羊膜創新轉化為常規臨床實踐。

生物創新、不斷演進的法規結構以及醫療服務模式的轉變意味著，只要相關人員能夠使其策略與臨床和營運實際情況相符，羊膜解決方案將成為現代再生醫學的重要組成部分。儘管保存技術和形態的多樣化拓展了實際應用範圍，但物流方面的考量和供體來源的選擇仍然是推廣應用的關鍵因素。貿易政策的變化和區域生產決策將繼續影響羊膜的取得和供應商競爭，凸顯了積極主動的供應鏈設計和與監管機構合作的重要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 羊膜市場：依形態

  • 冷凍保存
  • 脫水
  • 生的
  • 冷凍乾燥

第9章：羊膜市場：依來源分類

  • 牛
  • 馬
  • 人類

第10章 羊膜市場：依應用領域分類

  • 牙科
  • 眼科
  • 整形外科
  • 創傷治療

第11章：羊膜市場：依最終用戶分類

  • 門診手術中心
  • 診所
  • 醫院
  • 研究機構

第12章：羊膜市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：羊膜市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 羊膜市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國羊膜市場

第16章 中國羊膜市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Alliqua BioMedical, Inc.
  • Amniox Medical, LLC
  • Bio-Tissue, Inc.
  • Integra LifeSciences Corporation
  • MiMedx Group, Inc.
  • NuTech Medical, Inc.
  • Organogenesis Inc.
  • Osiris Therapeutics, Inc.
  • Smith & Nephew plc
  • TFC TissueTech, Inc.
  • VIVEX Biologics, Inc.
Product Code: MRR-036CEF50859B

The Amniotic Membrane Market was valued at USD 3.94 billion in 2025 and is projected to grow to USD 4.29 billion in 2026, with a CAGR of 9.28%, reaching USD 7.34 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.94 billion
Estimated Year [2026] USD 4.29 billion
Forecast Year [2032] USD 7.34 billion
CAGR (%) 9.28%

Comprehensive introduction to amniotic membrane science and clinical utility that frames current adoption drivers and innovation pathways across therapeutic domains

Amniotic membrane has emerged as a versatile biologic material with broad clinical utility driven by unique biological properties that support healing and tissue regeneration. Its extracellular matrix composition, inherent anti-inflammatory and anti-fibrotic factors, and relative immunological privilege make it an attractive adjunct across ophthalmic, wound care, dental, and orthopedic procedures. As stakeholders in surgery, regenerative medicine, and tissue engineering seek solutions that enhance patient outcomes while streamlining care pathways, amniotic membranes have transitioned from niche topical use toward integrated therapeutic applications.

Concurrent advances in preservation technologies, processing standards, and clinical evidence have expanded the contexts in which amniotic membrane products are deployed. Manufacturers are refining protocols to retain bioactivity while meeting sterility and storage expectations for varied clinical settings. Meanwhile, clinicians and hospital systems are increasingly interested in off-the-shelf formats that reduce handling complexity and support predictable performance. The interplay of innovation, regulatory scrutiny, and evolving clinical practice patterns forms the backdrop of the current landscape, underscoring the need for cross-functional alignment among R&D teams, quality and regulatory affairs, and commercial leaders as they plan product development and market entry strategies.

Transformative technological, regulatory, and care-delivery shifts reshaping amniotic membrane product design, clinical adoption, and procurement imperatives across healthcare systems

The amniotic membrane landscape is undergoing transformative shifts driven by technological, regulatory, and clinical forces that collectively reframe value propositions for manufacturers and care providers. Preservation and processing innovations such as optimized cryopreservation protocols, advanced dehydration techniques, and controlled lyophilization have improved shelf stability and logistics while preserving critical biological activity. These technical advances have catalyzed greater interest from specialties beyond ophthalmology, prompting product adaptations tailored to wound care matrices and orthopedic scaffolds.

On the regulatory front, agencies are clarifying pathways for tissue-derived products and emphasizing transparent donor screening, traceability, and validated processing controls. This increased regulatory attention is stimulating investments in quality systems and third-party audit readiness, which in turn elevate barriers to entry but also raise overall confidence among large institutional purchasers. Concurrently, reimbursement conversations are shifting toward value-based arguments grounded in reduced complication rates, faster healing, and lower downstream resource utilization, creating opportunities for evidence-based positioning. Transitioning care models, including ambulatory surgical expansion and outpatient procedural shifts, further influence product design and delivery system innovation. Together, these converging shifts are reshaping competitive dynamics and strategic priorities across the ecosystem.

Assessment of the broad downstream implications of 2025 tariff shifts on amniotic membrane supply chains, procurement choices, and regional manufacturing responses in clinical care

Trade policy changes and tariff adjustments enacted in 2025 have introduced renewed scrutiny of international supply chains and sourcing strategies for tissue-derived medical products. The imposition of tariffs can increase landed costs for imported raw materials and finished amniotic membrane formats, prompting manufacturers and purchasers to reassess procurement footprints and supplier relationships. In response, several manufacturers have accelerated localization of critical processing steps or diversified sourcing to mitigate exposure to single-country tariff impacts.

Clinicians and hospital procurement teams are evaluating the operational consequences of altered import economics, particularly for products that require specific preservation chains such as cryopreserved or lyophilized formats. Increased import costs may disproportionately affect products that rely on specialized cold-chain logistics or that originate from regions with concentrated donor programs. As a result, some institutions are prioritizing suppliers with regional manufacturing capabilities or integrated distribution networks to preserve continuity of care and predictable pricing. Additionally, regulatory compliance and donor tissue traceability remain central concerns as cross-border documentation becomes more complex under changing trade regimes. Looking ahead, organizations that proactively redesign supply agreements, invest in nearshoring, and enhance demand forecasting will be better positioned to withstand tariff-related volatility while maintaining clinical access to diverse product formats.

Granular segmentation analysis linking product formats, biological sources, clinical applications, and end-user environments to inform targeted development and commercialization pathways

Segmentation insights reveal differentiated dynamics across product form, biological source, clinical application, and end-user environment that collectively shape development priorities and adoption pathways. Based on Form, the market is studied across Cryopreserved, Dehydrated, Fresh, and Lyophilized, each presenting distinct benefits and logistical considerations: cryopreserved formats retain a high degree of bioactivity but demand cold-chain logistics, dehydrated and lyophilized forms improve shelf life and handling convenience while requiring validated rehydration protocols, and fresh formats can offer maximal native properties at the expense of immediate use constraints. Based on Source, the market is studied across Bovine, Equine, and Human, and each source carries different immunogenicity profiles, donor screening requirements, and clinician acceptance patterns that influence regulatory and ethical considerations.

Based on Application, the market is studied across Dental, Ophthalmic, Orthopedic, and Wound Healing, with each specialty driving distinct product design priorities such as thickness, flexibility, and biologic potency. For example, ophthalmic use emphasizes transparency and conformability, whereas orthopedic applications often prioritize structural integrity and integration with host tissue. Based on End User, the market is studied across Ambulatory Surgical Centers, Clinics, Hospitals, and Research Institutes, and the distribution strategy must reflect end-user preferences for ready-to-use formats, inventory turnover, and procurement cycle timelines. Taken together, these segmentation lenses underscore the need for modular product portfolios, tailored clinical evidence generation, and supply chain strategies that align with the operational realities of diverse care settings.

Regional dynamics and strategic manufacturing responses that drive differentiated clinical acceptance and supply resilience across the Americas, Europe Middle East & Africa, and Asia-Pacific markets

Regional dynamics exert a powerful influence on clinical adoption, regulatory expectations, and manufacturing strategy, with distinctly different trends observable across the Americas, Europe, Middle East & Africa, and Asia-Pacific regions. In the Americas, clinical practice patterns demonstrate rapid uptake in outpatient and specialty clinic settings, supported by established tissue banks and integrated distribution channels, although reimbursement frameworks vary and require evidence-driven positioning. In Europe, Middle East & Africa, regulatory harmonization efforts and strong emphasis on donor screening and traceability shape manufacturer investments in quality systems, while selective reimbursement policies create pockets of rapid adoption in center-led programs.

Asia-Pacific presents a diverse set of opportunities and challenges driven by a combination of rapid infrastructure expansion, variable regulatory regimes, and growing domestic tissue processing capabilities. Several countries have active translational research initiatives that accelerate local clinical validation, yet cold-chain logistics and varied procurement pathways necessitate adaptable commercial models. Across all regions, collaboration between manufacturers, large clinical centers, and regulatory authorities has proven instrumental in accelerating acceptance, and firms that tailor evidence packages to regional payer and clinician priorities achieve stronger engagement. Furthermore, regional manufacturing and nearshoring strategies have emerged as pragmatic responses to tariff and logistical pressures, enhancing supply resilience and reducing lead times for critical formats.

Competitive and strategic company behaviors highlighting manufacturing scale-up, vertical integration, evidence partnerships, and service-based differentiation driving market leadership

Leading organizations in the amniotic membrane sector are pursuing complementary strategies that combine technology refinement, quality system enhancement, and collaborative clinical validation. Many companies are investing in manufacturing scale-up and validated preservation workflows to ensure consistent product performance across varied formats. Others prioritize vertical integration, securing donor tissue pipelines and strengthening traceability to meet evolving regulatory scrutiny and to reassure large institutional purchasers. Strategic alliances with academic centers, specialty clinics, and wound care networks support evidence generation and create early adopter pathways that accelerate clinic-level acceptance.

Commercially, firms are differentiating through value-added services, such as clinical training, standardized application protocols, and outcome monitoring solutions that help clinicians maximize therapeutic benefits and document real-world performance. On the innovation front, emphasis on next-generation scaffolds, combination products, and hybrid constructs illustrates a commitment to expanding clinical utility while navigating regulatory complexity. Competitive positioning increasingly centers on demonstrable clinical outcomes, operational convenience, and supply reliability; companies that align R&D priorities with pragmatic clinical workflows and procurement needs establish stronger long-term relationships with health systems and specialty groups.

Actionable strategic priorities for manufacturers and clinical stakeholders to strengthen sourcing resilience, evidence generation, and service-led differentiation in amniotic membrane adoption

Industry leaders should pursue a coordinated set of actions to secure clinical adoption, operational resilience, and sustained innovation. First, diversify sourcing strategies and invest in regional processing capabilities to mitigate trade and logistical exposures while preserving product quality and traceability. Second, prioritize preservation and format optimization that align product characteristics with specific clinical workflows, reducing handling complexity for ambulatory and outpatient settings. Third, engage proactively with regulatory authorities and payer stakeholders to articulate value propositions grounded in clinical outcomes and reduced downstream resource utilization, thereby strengthening reimbursement dialogues.

In parallel, invest in targeted clinical evidence collection that demonstrates comparative performance across key applications, leveraging real-world data and pragmatic trial designs to accelerate uptake. Cultivate partnerships with leading clinical centers to co-develop training programs and standardized application protocols that reduce variability in outcomes. Finally, incorporate service-oriented commercial models that include clinician education, patient outcome tracking, and inventory management support to deepen relationships with hospital systems and surgical centers. By executing these strategic measures, organizations can enhance resilience, improve product-market fit, and create defensible differentiation in a dynamic clinical landscape.

Transparent, triangulated research methodology combining expert interviews, regulatory analysis, and scenario evaluation to support reproducible and actionable insights into amniotic membrane developments

This research synthesizes primary and secondary evidence using a triangulated approach designed to ensure accuracy, relevance, and reproducibility. Primary inputs included structured interviews with clinical thought leaders across ophthalmology, wound care, dental, and orthopedic specialties, supplemented by discussions with procurement professionals and regulatory experts to capture operational constraints and policy impacts. Secondary inputs incorporated peer-reviewed literature, regulatory guidance documents, conference proceedings, and validated technical white papers that illuminate preservation science and clinical outcomes. Data from multiple sources were cross-checked, and contrasting perspectives were reconciled through iterative expert validation to minimize bias and to ensure that conclusions reflect consensus where possible.

Analytical methods combined qualitative thematic analysis with process mapping to identify critical decision points in product selection and clinical workflows. Scenario analysis explored implications of supply chain disruptions and policy changes, while sensitivity checks tested assumptions about logistics and adoption barriers. Quality control measures included source verification, methodological documentation, and independent peer review of key findings. This layered methodology supports robust, actionable insights while maintaining transparency about data limitations and areas where additional primary research would strengthen confidence.

Concluding synthesis of clinical potential, operational constraints, and strategic imperatives that will determine which organizations translate amniotic membrane innovation into routine clinical practice

The convergence of biological innovation, evolving regulatory frameworks, and shifting care delivery models positions amniotic membrane solutions as a compelling component of modern regenerative care, provided stakeholders align strategy with clinical and operational realities. Preservation technologies and format diversity expand the range of viable use cases, yet logistical considerations and donor source choices remain pivotal determinants of adoption. Trade policy changes and regional manufacturing decisions will continue to shape access and supplier competitiveness, underscoring the importance of proactive supply chain design and regulatory engagement.

Ultimately, organizations that couple rigorous clinical evidence generation with pragmatic product design and responsive commercial models can accelerate clinical acceptance and realize durable partnerships with health systems and specialty providers. Strategic investments in quality systems, collaborative trials, and clinician-focused service offerings will differentiate leaders and drive better patient outcomes. As the ecosystem matures, measured, evidence-based approaches combined with operational adaptability will prove essential for translating scientific promise into routine clinical practice.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Amniotic Membrane Market, by Form

  • 8.1. Cryopreserved
  • 8.2. Dehydrated
  • 8.3. Fresh
  • 8.4. Lyophilized

9. Amniotic Membrane Market, by Source

  • 9.1. Bovine
  • 9.2. Equine
  • 9.3. Human

10. Amniotic Membrane Market, by Application

  • 10.1. Dental
  • 10.2. Ophthalmic
  • 10.3. Orthopedic
  • 10.4. Wound Healing

11. Amniotic Membrane Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Clinics
  • 11.3. Hospitals
  • 11.4. Research Institutes

12. Amniotic Membrane Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Amniotic Membrane Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Amniotic Membrane Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Amniotic Membrane Market

16. China Amniotic Membrane Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Alliqua BioMedical, Inc.
  • 17.6. Amniox Medical, LLC
  • 17.7. Bio-Tissue, Inc.
  • 17.8. Integra LifeSciences Corporation
  • 17.9. MiMedx Group, Inc.
  • 17.10. NuTech Medical, Inc.
  • 17.11. Organogenesis Inc.
  • 17.12. Osiris Therapeutics, Inc.
  • 17.13. Smith & Nephew plc
  • 17.14. TFC TissueTech, Inc.
  • 17.15. VIVEX Biologics, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL AMNIOTIC MEMBRANE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL AMNIOTIC MEMBRANE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES AMNIOTIC MEMBRANE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA AMNIOTIC MEMBRANE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY CRYOPRESERVED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY CRYOPRESERVED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY CRYOPRESERVED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY DEHYDRATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY DEHYDRATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY DEHYDRATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY FRESH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY FRESH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY FRESH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY LYOPHILIZED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY LYOPHILIZED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY LYOPHILIZED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY BOVINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY BOVINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY BOVINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY EQUINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY EQUINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY EQUINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY HUMAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY HUMAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY HUMAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY DENTAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY DENTAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY DENTAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY OPHTHALMIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY OPHTHALMIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY OPHTHALMIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY ORTHOPEDIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY ORTHOPEDIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY ORTHOPEDIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY WOUND HEALING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY WOUND HEALING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY WOUND HEALING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS AMNIOTIC MEMBRANE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS AMNIOTIC MEMBRANE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS AMNIOTIC MEMBRANE MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS AMNIOTIC MEMBRANE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS AMNIOTIC MEMBRANE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA AMNIOTIC MEMBRANE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA AMNIOTIC MEMBRANE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA AMNIOTIC MEMBRANE MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA AMNIOTIC MEMBRANE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA AMNIOTIC MEMBRANE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA AMNIOTIC MEMBRANE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA AMNIOTIC MEMBRANE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA AMNIOTIC MEMBRANE MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA AMNIOTIC MEMBRANE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA AMNIOTIC MEMBRANE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE, MIDDLE EAST & AFRICA AMNIOTIC MEMBRANE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA AMNIOTIC MEMBRANE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA AMNIOTIC MEMBRANE MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA AMNIOTIC MEMBRANE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA AMNIOTIC MEMBRANE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE AMNIOTIC MEMBRANE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE AMNIOTIC MEMBRANE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE AMNIOTIC MEMBRANE MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE AMNIOTIC MEMBRANE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE AMNIOTIC MEMBRANE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. MIDDLE EAST AMNIOTIC MEMBRANE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. MIDDLE EAST AMNIOTIC MEMBRANE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 79. MIDDLE EAST AMNIOTIC MEMBRANE MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST AMNIOTIC MEMBRANE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST AMNIOTIC MEMBRANE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. AFRICA AMNIOTIC MEMBRANE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. AFRICA AMNIOTIC MEMBRANE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 84. AFRICA AMNIOTIC MEMBRANE MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 85. AFRICA AMNIOTIC MEMBRANE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA AMNIOTIC MEMBRANE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC AMNIOTIC MEMBRANE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC AMNIOTIC MEMBRANE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC AMNIOTIC MEMBRANE MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC AMNIOTIC MEMBRANE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC AMNIOTIC MEMBRANE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. ASEAN AMNIOTIC MEMBRANE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. ASEAN AMNIOTIC MEMBRANE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 95. ASEAN AMNIOTIC MEMBRANE MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 96. ASEAN AMNIOTIC MEMBRANE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. ASEAN AMNIOTIC MEMBRANE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. GCC AMNIOTIC MEMBRANE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GCC AMNIOTIC MEMBRANE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 100. GCC AMNIOTIC MEMBRANE MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 101. GCC AMNIOTIC MEMBRANE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 102. GCC AMNIOTIC MEMBRANE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPEAN UNION AMNIOTIC MEMBRANE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPEAN UNION AMNIOTIC MEMBRANE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPEAN UNION AMNIOTIC MEMBRANE MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPEAN UNION AMNIOTIC MEMBRANE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPEAN UNION AMNIOTIC MEMBRANE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. BRICS AMNIOTIC MEMBRANE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. BRICS AMNIOTIC MEMBRANE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 110. BRICS AMNIOTIC MEMBRANE MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 111. BRICS AMNIOTIC MEMBRANE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. BRICS AMNIOTIC MEMBRANE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. G7 AMNIOTIC MEMBRANE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. G7 AMNIOTIC MEMBRANE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 115. G7 AMNIOTIC MEMBRANE MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 116. G7 AMNIOTIC MEMBRANE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 117. G7 AMNIOTIC MEMBRANE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. NATO AMNIOTIC MEMBRANE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. NATO AMNIOTIC MEMBRANE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 120. NATO AMNIOTIC MEMBRANE MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 121. NATO AMNIOTIC MEMBRANE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 122. NATO AMNIOTIC MEMBRANE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL AMNIOTIC MEMBRANE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. UNITED STATES AMNIOTIC MEMBRANE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 125. UNITED STATES AMNIOTIC MEMBRANE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 126. UNITED STATES AMNIOTIC MEMBRANE MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 127. UNITED STATES AMNIOTIC MEMBRANE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. UNITED STATES AMNIOTIC MEMBRANE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. CHINA AMNIOTIC MEMBRANE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 130. CHINA AMNIOTIC MEMBRANE MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 131. CHINA AMNIOTIC MEMBRANE MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 132. CHINA AMNIOTIC MEMBRANE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. CHINA AMNIOTIC MEMBRANE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)